Children's brain tumour drug delivery consortium by Rahman, Ruman et al.
Children's brain tumour drug delivery consortium 
Ruman Rahman [1], Richard Grundy [1], Emma Campbell [1], Henry Brem [2], Monica Pearl [2], Jordan 
Green [2], Miroslav Janowski [2], Kenneth Cohen [2], Piotr Walczak [2], Katherine Warren [3], Stephen 
Lowis [4], Alexander Mullen [5], Marie Boyd [5], Gareth Veal [6], Darren Hargrave [7], Dannis van Vuurden 
[8], Stephen Powell [9], and David Walker [10]  
1 Children’s Brain Tumour Research Centre, www.cbtrc.org, University of Nottingham, Nottingham, UK,  
2 Johns Hopkins University, Baltimore, MD, USA,  
3 National Cancer Institute, Bethesda, MD, USA,  
4 Bristol Royal Hospital for Children, Bristol, UK,  
5 University of Strathclyde, Strathclyde, UK,  
6 Newcastle University, Newcastle, UK,  
7 University College London, London, UK,  
8 Institute of Child Health, London, UK,  
9 VU University Medical Center, Amsterdam, The Netherlands,  
10 Fast Track Pharma Limited, London, UK. 
 
INTRODUCTION: Whilst there is an urgent need to expedite the development of new or repurposed drugs 
for children’s cancer, the additional challenge in the developing brain is to ensure the drug is delivered to 
the tumour at therapeutic and non-toxic concentrations for sufficient duration to achieve the biological 
effect. This is the necessary focus for personalised medicine agendas in children’s brain tumours as they 
account for over 20% of child - hood cancer and differ significantly in their biological characteristics from 
their adult counterparts. METHODS: The authors took part in an international CNS drug delivery London 
workshop funded by the charity Children with Cancer UK (CwC) in February 2016 where different 
experimental techniques aimed at optimising CNS drug delivery in children’s brain tumours were presented 
and discussed. RESULTS: The workshop was reported (1) and promoted through e-cancer (2). We were 
encouraged to develop a proposal, to establish an international research consortium to raise awareness 
and promote collaboration in the field. This is now to be funded for two years by Children with Cancer. The 
Children’s Brain Tumour Drug Delivery Consortium will organise and host discussions between an 
international, multi-disciplinary network of clinicians and researchers within pharma and academia as well 
as a range of funders and stakeholders. This Consortium seeks to strengthen collaborative developments by 
working closely with the international children’s brain tumour community. CONCLUSION: We present this 
abstract to the SNO Pediatric conference to launch this initiative in North America and invite collaborators 
to promote this research priority for children across the world and to consider joining the consortium, 
which will be presented at the conference. 
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